2023-05-03 17:51:37 ET
- Evolent Health press release ( NYSE: EVH ): Q1 Non-GAAP EPS of $0.20.
- Revenue of $427.7M (+44.0% Y/Y).
- Selling, general and administrative expenses of $89.7 million and $58.9 million for the three months ended March 31, 2023 and 2022, respectively.
- Net loss attributable to common shareholders of Evolent Health, Inc. of $(26.3) million and $(5.4) million for the three months ended March 31, 2023 and 2022, respectively.
-
Total cash and cash equivalents was $157.5 million as of March 31, 2023.
-
Adjusted EBITDA of $50.5 million and $24.3 million for the three months ended March 31, 2023 and 2022, respectively.
- Adjusted EBITDA margin of 11.8% and 8.2% for the three months ended March 31, 2023 and 2022, respectively.
- Adjusted income attributable to common shareholders of $22.1 million and $10.4 million for the three months ended March 31, 2023 and 2022, respectively.
For further details see:
Evolent Health Non-GAAP EPS of $0.20, revenue of $427.7M